CA2757189A1 - Cristaux de bromhydrate de prasugrel - Google Patents

Cristaux de bromhydrate de prasugrel Download PDF

Info

Publication number
CA2757189A1
CA2757189A1 CA2757189A CA2757189A CA2757189A1 CA 2757189 A1 CA2757189 A1 CA 2757189A1 CA 2757189 A CA2757189 A CA 2757189A CA 2757189 A CA2757189 A CA 2757189A CA 2757189 A1 CA2757189 A1 CA 2757189A1
Authority
CA
Canada
Prior art keywords
ang
crystal
alpha
acetic acid
prasugrel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2757189A
Other languages
English (en)
Other versions
CA2757189C (fr
Inventor
Zhedong Yuan
Xingdong Cheng
Yulei Yang
Ling Tong
Xiong Yu
Laifang Zhang
Wenliang Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Pharmaceutical Industry
Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd
Original Assignee
Shanghai Institute of Pharmaceutical Industry
Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Pharmaceutical Industry, Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd filed Critical Shanghai Institute of Pharmaceutical Industry
Publication of CA2757189A1 publication Critical patent/CA2757189A1/fr
Application granted granted Critical
Publication of CA2757189C publication Critical patent/CA2757189C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA2757189A 2009-03-31 2010-03-31 Cristaux de bromhydrate de prasugrel Active CA2757189C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200910030050 2009-03-31
CN200910030050.3 2009-03-31
PCT/CN2010/071464 WO2010111951A1 (fr) 2009-03-31 2010-03-31 Cristaux de bromhydrate de prasugrel

Publications (2)

Publication Number Publication Date
CA2757189A1 true CA2757189A1 (fr) 2010-10-07
CA2757189C CA2757189C (fr) 2016-02-16

Family

ID=42827491

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2757189A Active CA2757189C (fr) 2009-03-31 2010-03-31 Cristaux de bromhydrate de prasugrel

Country Status (7)

Country Link
US (1) US8772488B2 (fr)
EP (1) EP2415774B1 (fr)
JP (1) JP5501438B2 (fr)
CN (1) CN102365288B (fr)
CA (1) CA2757189C (fr)
RU (1) RU2484094C1 (fr)
WO (1) WO2010111951A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2757189C (fr) 2009-03-31 2016-02-16 Shanghai Institute Of Pharmaceutical Industry Cristaux de bromhydrate de prasugrel
US8802854B2 (en) 2010-04-08 2014-08-12 Teva Pharmaceutical Industries Ltd. Crystalline forms of Prasugrel salts
CZ305314B6 (cs) * 2010-12-30 2015-07-29 Zentiva, K.S. Nový hydrobromid formy C 5-[2-cyklopropyl-1-(2-fluorofenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráněným názvem prasugrel a způsob jeho výroby
US8603537B2 (en) 2012-04-02 2013-12-10 Egis Pharmaceuticals Plc Prasugrel containing quickly released stable oral pharmaceutical compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
KR20030014294A (ko) * 2000-07-06 2003-02-15 상꾜 가부시키가이샤 히드로피리딘 유도체 산부가염
US20100204470A1 (en) * 2006-06-27 2010-08-12 Sandoz Ag method for salt preparation
CN101255169B (zh) * 2008-03-26 2010-11-10 山东大学 普拉格雷盐及其制备方法
CA2757189C (fr) 2009-03-31 2016-02-16 Shanghai Institute Of Pharmaceutical Industry Cristaux de bromhydrate de prasugrel
EP2451816A4 (fr) 2009-07-06 2013-02-27 Glenmark Generics Ltd Forme cristalline d'hydrobromure de prasugrel et son procédé de préparation

Also Published As

Publication number Publication date
RU2484094C1 (ru) 2013-06-10
US20120095035A1 (en) 2012-04-19
CA2757189C (fr) 2016-02-16
US8772488B2 (en) 2014-07-08
EP2415774A1 (fr) 2012-02-08
EP2415774B1 (fr) 2014-07-09
JP2012522023A (ja) 2012-09-20
CN102365288B (zh) 2014-04-09
EP2415774A4 (fr) 2013-01-02
CN102365288A (zh) 2012-02-29
JP5501438B2 (ja) 2014-05-21
WO2010111951A1 (fr) 2010-10-07

Similar Documents

Publication Publication Date Title
EP2112155B1 (fr) Sel hydrogénosulfate de 2-acétoxy-5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tétrahydrothiéno[3,2-c]pyridine et sa préparation
EP1440969A1 (fr) Cristal a forme alpha ou beta d'un derive acetanilinide
WO2007114526A1 (fr) Procede de production de prasugrel de grande purete et sel d'addition d'acide de celui-ci
EP1615645B2 (fr) Forme cristalline iii de chlorhydrate de moxifloxacine anhydre et procede de preparation de cette derniere
WO2001014379A2 (fr) Nouvelle forme cristalline de disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-l- sel d'acide glutamique et procedes de preparation
JP2007302658A (ja) イマチニブメシレートの多形フォーム及び新規結晶フォーム及び非晶フォーム並びにフォームαの調製方法
CA2757189C (fr) Cristaux de bromhydrate de prasugrel
TWI496773B (zh) Ｎ－［２－［［（２，３－二氟苯基）甲基］硫基］－６－｛［（１ｒ，２ｓ）－２，３－二羥基－１－甲基丙基］氧基｝－４－嘧啶基］－１－三亞甲亞胺磺醯胺之新穎結晶型
JP6185490B2 (ja) ３−（４−ニトロ−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンの固体形態
WO2006023676A1 (fr) Sel de napsylate de clopidogrel
RU2256666C2 (ru) Кристаллические формы производного пиримидинового нуклеозида (варианты), фармацевтическая композиция, способ профилактики и лечения опухолевых заболеваний и применение кристаллической формы
CN109843300B (zh) 一种化合物的结晶多晶型形式
KR101552691B1 (ko) 신규한 항-혈소판 화합물의 부가염
EP3985009B1 (fr) Forme cristalline b de composé de tétrahydrothiénopyridine, son procédé de préparation, composition et application
KR102170422B1 (ko) 토파시티닙의 신규 염, 이의 제조방법 및 이를 포함하는 약학 조성물
KR20200134928A (ko) 발사르탄/사쿠비트릴 3소듐염 수화물의 결정형 및 그 제조방법
KR20110024057A (ko) 신규한 프라수그렐 황산수소염의 결정다형
WO2009087151A1 (fr) Formes polymorphes de chlorhydrate de moxifloxacine et leurs procédés de préparation
KR20180124428A (ko) 결정형 사쿠비트릴 헤미나트륨염, 이의 제조방법 및 이를 포함하는 약학 조성물
KR20180124400A (ko) 사쿠비트릴 결합체, 이의 제조방법 및 이를 포함하는 약학 조성물
EP1163241A1 (fr) Sels de zolpidem
HU230483B1 (hu) Erlotinib sók
KR20110015254A (ko) 프라수그렐 디술폰산염 및 이의 결정
CN115536654A (zh) 小檗碱橙皮素盐晶型及其制备方法和其组合物与应用
KR20110026662A (ko) 베포타스틴 살리실산염, 이의 제조방법 및 이를 유효성분으로 포함하는 항히스타민 또는 항알레르기용 약학적 조성물

Legal Events

Date Code Title Description
EEER Examination request